Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases
- Erica A. Moehle,
- Jeremy M. Rock,
- Ya-Li Lee,
- Yann Jouvenot,
- Russell C. DeKelver,
- Philip D. Gregory,
- Fyodor D. Urnov*, and
- Michael C. Holmes
- Sangamo BioSciences, Inc., Point Richmond Technology Center, 501 Canal Boulevard, Suite A100, Richmond, CA 94804
-
Communicated by Carl O. Pabo, Harvard Medical School, Boston, MA, December 27, 2006 (received for review November 14, 2006)
Abstract
Efficient incorporation of novel DNA sequences into a specific site in the genome of living human cells remains a challenge despite its potential utility to genetic medicine, biotechnology, and basic research. We find that a precisely placed double-strand break induced by engineered zinc finger nucleases (ZFNs) can stimulate integration of long DNA stretches into a predetermined genomic location, resulting in high-efficiency site-specific gene addition. Using an extrachromosomal DNA donor carrying a 12-bp tag, a 900-bp ORF, or a 1.5-kb promoter-transcription unit flanked by locus-specific homology arms, we find targeted integration frequencies of 15%, 6%, and 5%, respectively, within 72 h of treatment, and with no selection for the desired event. Importantly, we find that the integration event occurs in a homology-directed manner and leads to the accurate reconstruction of the donor-specified genotype at the endogenous chromosomal locus, and hence presumably results from synthesis-dependent strand annealing repair of the break using the donor DNA as a template. This site-specific gene addition occurs with no measurable increase in the rate of random integration. Remarkably, we also find that ZFNs can drive the addition of an 8-kb sequence carrying three distinct promoter-transcription units into an endogenous locus at a frequency of 6%, also in the absence of any selection. These data reveal the surprising versatility of the specialized polymerase machinery involved in double-strand break repair, illuminate a powerful approach to mammalian cell engineering, and open the possibility of ZFN-driven gene addition therapy for human genetic disease.
Footnotes
- *To whom correspondence should be addressed. E-mail: furnov{at}sangamo.com
-
Author contributions: E.A.M. and J.M.R. contributed equally to this work; E.A.M., J.M.R., P.D.G., F.D.U., and M.C.H. designed research; E.A.M., J.M.R., Y.-L.L., Y.J., R.C.D., and F.D.U. performed research; E.A.M., J.M.R., F.D.U., and M.C.H. analyzed data; and P.D.G., F.D.U., and M.C.H. wrote the paper.
-
Conflict of interest statement: C.O.P. is chair of the Scientific Advisory Board for Sangamo BioSciences, Inc. E.A.M., J.M.R., Y.-L.L., Y.J., R.C.D., P.D.G., F.D.U., and M.C.H. are full-time employees of Sangamo BioSciences, Inc.
-
This article contains supporting information online at www.pnas.org/cgi/content/full/0611478104/DC1.
- Abbreviations:
- ZFN,
- zinc finger nuclease;
- DSB,
- double-strand break;
- HDR,
- homology-directed repair;
- SDSA,
- synthesis-dependent strand annealing.
-
Freely available online through the PNAS open access option.
- © 2007 by The National Academy of Sciences of the USA





